Synairgen PLC is a UK-based respiratory company focused on drug discovery, development and commercialisation.
The company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs.
SNG001 has been granted Fast Track status from the US Food and Drug Administration (FDA).
Synairgen was founded by University of Southampton Professors Sir Stephen Holgate, Donna Davies and Ratko Djukanovic in 2003.